The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, will host a free webinar on the US Food and Drug Administration (FDA) final rule that seeks to regulate laboratory developed tests (LDTs) as medical devices.
The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, today released the results of its Impacts of the European Union (EU) In Vitro Diagnostic Regulation (IVDR) Survey. The anonymous survey was created and administered to molecular diagnostics professionals around the world to determine current levels of understanding, assess broad implications, and identify future trends related to the new regulation.
The Association for Molecular Pathology (AMP) has published a report that explores specific considerations for a slice testing strategy for diagnostics, including gene selection, analytic performance, coverage, quality, and interpretation.
The Association for Molecular Pathology (AMP), the premier global molecular diagnostic professional society, today announced the appointment of Lauren S. Menser, CAE, as its Chief Executive Officer, effective January 3, 2024.
The Association for Molecular Pathology has published best practice recommendations for validating and reporting clinical circulating tumor DNA (ctDNA) or liquid biopsy assays and their related scientific publications.
The Association for Molecular Pathology (AMP) has announced the recipients of this year’s Award for Excellence in Molecular Diagnostics, Jeffrey A. Kant Leadership Award and Meritorious Service Award.
The Association for Molecular Pathology (AMP) has published a review of the current benefits and challenges to using multiplex PCR panels for the detection of microbial pathogens from gastrointestinal, central nervous system, lower respiratory tract, and joint specimens.
The Association for Molecular Pathology (AMP), the premier global molecular diagnostic professional society, today published consensus recommendations to aid in the design and validation of clinical CYP3A4 and CYP3A5 genotyping assays, promote standardization of testing across different laboratories, and improve patient care.
The Association for Molecular Pathology (AMP) today awarded Xavier Becerra, US Secretary of the Department of Health and Human Services, with its Champion for Innovation Award. Secretary Becerra was recognized for his 30-year career in public service and his ongoing commitment to protecting patient access to high-quality, affordable care. The award presentations coincides with the 10th anniversary of the Supreme Court’s landmark decision invalidating gene patents in Association for Molecular Pathology et al. v. Myriad Genetics, Inc. et al.
The Association for Molecular Pathology (AMP) has published a report that was designed to establish recommendations for standardizing orthogonal confirmation practices for germline variants detected by next-generation sequencing (NGS) in The Journal of Molecular Diagnostics.
The Association for Molecular Pathology (AMP) applauds Congress for reaching an agreement on the Consolidated Appropriations Act of 2023 and recognizing that it was not the appropriate mechanism for advancing the Verifying Accurate Leading-edge IVCT Development (VALID) Act. The VALID Act proposed dramatic oversight modifications that would have been disruptive to clinical testing laboratories and harmful to patients throughout the U.S.
The Association for Molecular Pathology (AMP), the premier global molecular diagnostic professional society, has published a report that was designed to assess clinical adoption, identify classification inconsistencies, and evaluate implementation barriers for the 2017 report, “Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.” The AMP manuscript, “Assessments of Somatic Variant Classification Using the AMP/ASCO/CAP Guidelines” was released online ahead of publication in The Journal of Molecular Diagnostics.
The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, has published “Recommendations for the Use of In Silico Approaches for Next Generation Sequencing Bioinformatic Pipeline Validation: A Joint Report of the Association for Molecular Pathology, Association for Pathology Informatics, and College of American Pathologists.”
The Association for Molecular Pathology (AMP), the premier global, molecular diagnostics professional society, today announced the recipients of this year’s Award for Excellence in Molecular Diagnostics, Jeffrey A. Kant Leadership Award and Meritorious Service Award. These prestigious accolades will be presented this November during AMP’s 2022 Annual Meeting & Expo in Phoenix, Arizona.
The Association for Molecular Pathology (AMP), the premier global molecular diagnostic professional society, today published consensus recommendations to aid in the design and validation of clinical TPMT and NUDT15 genotyping assays, promote standardization of testing across different laboratories and improve patient care.
The Association for Molecular Pathology (AMP) today released a report entitled “Economics of Clinical Testing during a Public Health Emergency: Lessons Learned from Two Years of COVID-19.” The detailed assessment reflects on the first two years of the COVID-19 pandemic, dissects various coding, coverage, and pricing policies, and provides 15 recommendations to help prevent or at least mitigate these same economic challenges in the future.
The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, called on Congress to allow for a thorough evaluation of the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021, or any other legislation to change regulations for laboratory developed testing procedures (LDPs). Representatives from AMP, the American Association for Clinical Chemistry (AACC), the American College of Medical Genetics and Genomics (ACMG), and the Association of Pathology Chairs (APC) hosted a congressional briefing yesterday to educate lawmakers about how diagnostic tests are currently regulated and the substantial impact the VALID Act would have on clinical testing laboratories, healthcare providers, and patients throughout the U.S.
The Association for Molecular Pathology (AMP), the premier global, molecular diagnostics professional society, today announced the appointment of Ronald M. Przygodzki, MD as the incoming Editor-in-Chief of The Journal of Molecular Diagnostics (JMD). Barbara Zehnbauer, PhD, who has served with distinction as Editor-in-Chief since January 2015, will retire from the position effective March 1, 2022.
The Association for Molecular Pathology (AMP), the premier global, molecular diagnostics professional society, today announced the recipients of this year’s Award for Excellence in Molecular Diagnostics, Jeffrey A. Kant Leadership Award and Meritorious Service Award.
The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, today announced a new article in JAMA Health Forum.
The Association for Molecular Pathology (AMP) today released recommendations to support and facilitate sharing of variant data through the use of public repositories.
The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, today published consensus recommendations to aid in the design and validation of clinical CYP2D6 assays, promote standardization of testing across different laboratories and improve patient care. The manuscript, “Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and European Society for Pharmacogenomics and Personalized Therapy,” was released online ahead of publication in The Journal of Molecular Diagnostics.
The Association for Molecular Pathology (AMP) and the Association of Pathology Chairs (APC) commend U.S. Senator Rand Paul (R-KY) for introducing legislation that would allow molecular pathology professionals to continue advancing and offering high-quality laboratory developed testing procedures (LDPs) for patient care. The Verified Innovative Testing in American Laboratories (VITAL) Act of 2021 would enhance transparency, preserve innovation, and ensure widespread patient access to essential medical services.
The Association for Molecular Pathology (AMP) has released the results of its qualitative and quantitative “Analysis of Professional Work Effort in Molecular Test Interpretation Report.” More than 100 molecular professionals reported that their efforts spent on data analysis, interpretation, and reporting for molecular diagnostic tests were not sufficiently reimbursed. Respondents indicated that adequate reimbursement for these activities would improve patient care by increasing access to these essential medical services and enabling more data-driven treatment decisions.
The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, today released the preliminary results of its “Molecular Testing for Cancer during COVID-19” survey of clinical laboratories.
The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, today announced the formation of the AMP COVID Response (ACR) Steering Committee to help coordinate and communicate the organization’s continued efforts to guide diagnostic testing during the ongoing COVID-19 pandemic and preparations for future emerging outbreaks.
The Association for Molecular Pathology (AMP) has released the preliminary results of its August 2020 SARS-CoV-2 Testing Survey for clinical laboratories. Respondents are experiencing continued supply chain interruptions and significant staffing shortages, all while demand for molecular diagnostic testing continues to increase.
The Association for Molecular Pathology (AMP), the premier global, molecular diagnostics professional society, today announced the recipients of this year’s Award for Excellence in Molecular Diagnostics, Jeffrey A. Kant Leadership Award and Meritorious Service Award.
The Association for Molecular Pathology (AMP), the premier global, molecular diagnostics professional society, commends the decision by the U.S. Department of Health and Human Services (HHS) to rescind the requirement for premarket review of laboratory developed testing procedures (LDPs) by the Food and Drug Administration (FDA).
The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, today released the preliminary results of its April 2020 SARS-CoV-2 Testing Survey for clinical laboratories. The anonymous survey was created and administered to document clinical laboratory efforts and experiences. The results will be used to help inform future advocacy and clinical practice programs related to pandemic responses.
AMP has published consensus, evidence-based recommendations to aid in the design, validation and interpretation of clinical genotyping tests for the prediction of warfarin response. The manuscript, “Recommendations for Clinical Warfarin Sensitivity Genotyping Allele Selection: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists,” was released online ahead of publication in The Journal of Molecular Diagnostics.
AMP has submitted a formal response in support of the Citizen Petition from Hyman, Phelps & McNamara, P.C. on behalf of the Coalition to Preserve Access to Pharmacogenomics (PGx) Information. The response builds on AMP’s PGx Best Practices Statement and includes a series of recommendations that will rectify recent FDA actions, which have suppressed important patient safety information.
AMP applauds US Senator Rand Paul (R-KY) for introducing new legislation to allow molecular pathology professionals to continue advancing and offering laboratory developed testing procedures (LDPs) for patient care. The Verified Innovative Testing in American Laboratories (VITAL) Act of 2020
clarifies the federal regulatory authority over LDPs and encourages the modernization of the existing Clinical
Laboratory Improvement Amendments (CLIA), which are administered by the Centers for Medicare and
Medicaid Services(CMS). The legislation was designed to enhance transparency, preserve innovation and ensure widespread patient access to essential medical services.
The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, today released a statement on H.R. 6201, the Families First Coronavirus Response Act, as passed by the House of Representatives on March 14, 2020.
AMP has announced the recipients of this year’s Award for Excellence in Molecular Diagnostics, Jeffrey A. Kant Leadership Award and Meritorious Service Award. These prestigious accolades will be presented this November during AMP’s 25th Annual Meeting & Expo in Baltimore, Maryland.
AMP has published a new position statement for pharmacogenomic testing. Based on a recent assessment of the current market landscape, the statement includes a list of criteria for laboratories to follow for these types of tests to ensure responsible use, preserve broad access and improve patient care.
AMP has revised its official position for all consumer genomic testing. Based on a recent assessment of the current market landscape and privacy best practices, the latest position statement features an expanded list of conditions that must be met before AMP can support a clinically-meaningful test.
AMP has expressed serious concerns with Congress’ recent proposal to amend Section 101 of the Patent Act. If enacted, the draft legislation would overturn 150 years of patent case law and permit patenting of human genes and naturally-occurring associations between genes and diseases.
A new joint report from AMP and CAP shares consensus, evidence-based recommendations to aid in the design and validation of clinical CYP2C9 assays, promote standardization of testing across different laboratories and improve patient care.
Leading health care companies and organizations representing patients, providers, academic medical centers, laboratories, and diagnostic manufacturers urged the Centers for Medicare and Medicaid Services to revise its interpretation of the National Coverage Determination for Next Generation Sequencing.
AMP has announced the recipients of this year’s Award for Excellence in Molecular Diagnostics, Jeffrey A. Kant Leadership Award and Meritorious Service Award. These prestigious accolades will be presented in November during the AMP 2018 Annual Meeting & Expo in San Antonio, Texas.
AMP has published consensus, evidence-based recommendations to aid clinical laboratory professionals with the management of most Chronic Myeloid Neoplasms (CMNs) and development of high-throughput pan-myeloid sequencing testing panels.
AMP has published consensus, evidence-based recommendations to aid clinical laboratory professionals when designing and validating clinical CYP2C19 assays, promote standardization of testing across different laboratories and complement existing clinical guidelines.
The Association for Molecular Pathology, the premier global, non-profit molecular diagnostics professional society, today published 17 consensus recommendations to help clinical laboratory professionals achieve high-quality sequencing results and deliver better patient care.
September 5, 2017 – The Association for Molecular Pathology (AMP), the premier global, non-profit organization serving molecular diagnostics professionals, today announced the recipients of this year’s Jeffrey A. Kant Leadership and AMP Meritorious Service Awards.
AMP has published consensus recommendations that will help clinical laboratory professionals achieve high-quality sequencing results and deliver better care for cancer patients
AMP has published guideline recommendations for both clinical laboratory professionals and oncologists that assess the status of next-generation sequencing (NGS)-based cancer tests and establish standardized classification, annotation, interpretation, and reporting conventions for somatic sequence variants.